GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
NCT04401475 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect78/100
StatusTERMINATED
PhasePHASE2 / PHASE3
Lead sponsorEdesa Biotech Inc.
Last update2026-10-26
Public-record facts
| Intervention | SOC plus 15mg/kg EB05 IV (BIOLOGICAL) |
|---|---|
| Condition | COVID-19, ARDS |
| Enrollment | 278 |
| Why stopped | Edesa has made the decision to terminate this study solely for business reasons. The study termination was not related to any safety concerns. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-26.
- It is an interventional PHASE2/PHASE3 study with a named biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT04401475. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.